INmune Bio, Inc.

NasdaqCM INMB

INmune Bio, Inc. Total Non-Current Liabilities for the quarter ending September 30, 2024: USD 284.00 K

INmune Bio, Inc. Total Non-Current Liabilities is USD 284.00 K for the quarter ending September 30, 2024, a -92.13% change year over year. Total non-current liabilities are the sum of long-term debt and other non-current liabilities.
  • INmune Bio, Inc. Total Non-Current Liabilities for the quarter ending September 30, 2023 was USD 3.61 M, a -72.65% change year over year.
  • INmune Bio, Inc. Total Non-Current Liabilities for the quarter ending September 30, 2022 was USD 13.20 M, a -9.64% change year over year.
  • INmune Bio, Inc. Total Non-Current Liabilities for the quarter ending September 30, 2021 was USD 14.61 M, a 10,637.05% change year over year.
  • INmune Bio, Inc. Total Non-Current Liabilities for the quarter ending September 30, 2020 was USD 136.04 K, a -20.68% change year over year.
Key data
Date Total Non-Current Liabilities Shareholders' Equity Other Liabilities Total Liabilities
Market news
Loading...
SV Wall Street
NasdaqCM: INMB

INmune Bio, Inc.

CEO Dr. Raymond Joseph Tesi M.D.
IPO Date Feb. 4, 2019
Location United States
Headquarters 225 NE Mizner Boulevard
Employees 11
Sector Healthcare
Industries
Description

INmune Bio, Inc., a clinical-stage immunotherapy company, focuses on developing drugs to reprogram the patient's innate immune system to treat disease. The company develops and commercializes product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation. Its development programs include INKmune, which focuses on treating women with relapse refractory ovarian carcinoma and patients with high-risk myelodysplastic syndrome; INB03, an immunotherapy that treats patients with hematologic malignancies and solid tumors; and XPro1595 for the treatment of Alzheimer's disease. The company has license agreements with Xencor, Inc.; Immune Ventures, LLC; University of Pittsburg; and University College London. INmune Bio, Inc. was incorporated in 2015 and is headquartered in Boca Raton, Florida.

Similar companies

PYPD

PolyPid Ltd.

USD 2.86

-4.35%

BIVI

BioVie Inc.

USD 1.65

-1.20%

DRMA

Dermata Therapeutics, Inc.

USD 1.23

2.50%

AVXL

Anavex Life Sciences Corp.

USD 9.27

-3.14%

CUE

Cue Biopharma, Inc.

USD 1.45

6.62%

ANTX

AN2 Therapeutics, Inc.

USD 1.14

-2.56%

AVTE

Aerovate Therapeutics, Inc.

USD 2.62

0.00%

TCRX

TScan Therapeutics, Inc.

USD 2.57

-0.39%

SAVA

Cassava Sciences, Inc.

USD 2.38

0.00%

ANEB

Anebulo Pharmaceuticals, Inc.

USD 1.54

-3.15%

ANIX

Anixa Biosciences, Inc.

USD 2.90

-1.36%

StockViz Staff

February 4, 2025

Any question? Send us an email